Literature DB >> 27622336

Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.

Zhong-Qiang Guo1, Tong Zheng2, Baoen Chen3, Cheng Luo4, Sisheng Ouyang4, Shouzhe Gong3, Jiafei Li3, Liu-Liang Mao5, Fulin Lian6, Yong Yang7, Yue Huang2, Li Li3, Jing Lu8, Bidong Zhang9, Luming Zhou10, Hong Ding4, Zhiwei Gao7, Liqun Zhou11, Guoqiang Li12, Ran Zhou4, Ke Chen12, Jingqiu Liu4, Yi Wen6, Likun Gong8, Yuwen Ke12, Shang-Dong Yang5, Xiao-Bo Qiu10, Naixia Zhang6, Jin Ren8, Dafang Zhong7, Cai-Guang Yang13, Jiang Liu14, Hualiang Jiang15.   

Abstract

In the cytoplasm of virtually all clear-cell renal cell carcinoma (ccRCC), speckle-type POZ protein (SPOP) is overexpressed and misallocated, which may induce proliferation and promote kidney tumorigenesis. In normal cells, however, SPOP is located in the nucleus and induces apoptosis. Here we show that a structure-based design and subsequent hit optimization yield small molecules that can inhibit the SPOP-substrate protein interaction and can suppress oncogenic SPOP-signaling pathways. These inhibitors kill human ccRCC cells that are dependent on oncogenic cytoplasmic SPOP. Notably, these inhibitors minimally affect the viability of other cells in which SPOP is not accumulated in the cytoplasm. Our findings validate the SPOP-substrate protein interaction as an attractive target specific to ccRCC that may yield novel drug discovery efforts.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27622336     DOI: 10.1016/j.ccell.2016.08.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  33 in total

1.  Kidney cancer: On target - inhibiting SPOP in ccRCC.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2016-10-04       Impact factor: 14.432

2.  The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells.

Authors:  Xianjiang Lan; Eugene Khandros; Peng Huang; Scott A Peslak; Saurabh K Bhardwaj; Jeremy D Grevet; Osheiza Abdulmalik; Hongxin Wang; Cheryl A Keller; Belinda Giardine; Josue Baeza; Emily R Duffner; Osama El Demerdash; Xiaoli S Wu; Christopher R Vakoc; Benjamin A Garcia; Ross C Hardison; Junwei Shi; Gerd A Blobel
Journal:  Blood Adv       Date:  2019-05-28

Review 3.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

4.  Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.

Authors:  Remi Adelaiye-Ogala; Nur P Damayanti; Ashley R Orillion; Sreevani Arisa; Sreenivasulu Chintala; Mark A Titus; Chinghai Kao; Roberto Pili
Journal:  Cancer Res       Date:  2018-03-23       Impact factor: 12.701

5.  SPOP regulates the DNA damage response and lung adenocarcinoma cell response to radiation.

Authors:  Yiping Dong; Dan Zhang; Mengjiao Cai; Zhenzhen Luo; Yue Zhu; Liuyun Gong; Yutiantian Lei; Xinyue Tan; Qing Zhu; Suxia Han
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

6.  Uterine function in the mouse requires speckle-type poz protein.

Authors:  Lan Hai; Maria M Szwarc; Bin He; David M Lonard; Ramakrishna Kommagani; Francesco J DeMayo; John P Lydon
Journal:  Biol Reprod       Date:  2018-06-01       Impact factor: 4.285

Review 7.  SPOP and cancer: a systematic review.

Authors:  Alison Clark; Marieke Burleson
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 8.  The ubiquitin ligase adaptor SPOP in cancer.

Authors:  Matthew J Cuneo; Tanja Mittag
Journal:  FEBS J       Date:  2019-09-18       Impact factor: 5.542

Review 9.  Ubiquitin ligases in oncogenic transformation and cancer therapy.

Authors:  Daniela Senft; Jianfei Qi; Ze'ev A Ronai
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

10.  SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors.

Authors:  Xiangpeng Dai; Zhiwei Wang; Wenyi Wei
Journal:  Cell Cycle       Date:  2017       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.